XNASSXTC
Market cap1mUSD
Dec 23, Last price
0.35USD
1D
8.34%
1Q
-46.25%
IPO
-94.33%
Name
China SXT Pharmaceuticals Inc
Chart & Performance
P/E
—
P/S
0.62
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
142.78%
Rev. gr., 5y
-22.75%
Revenues
2m
-2.19%
Net income
-3m
L-47.79%
CFO
-2m
L+2,287.47%
Profile
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine piece tablets (TCMP) in China. The company offers advanced, fine, and regular TCMP products, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. As of March 31, 2022, it had an end-customer base of 68 pharmaceutical companies, 14 chain pharmacies, and 20 hospitals in 10 provinces and municipalities in China. The company was founded in 2005 and is headquartered in Taizhou, China.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | 2016‑03 | |
| Income | |||||||||
Revenues | 1,928 -2.19% | 1,972 -24.23% | 2,602 -45.53% | ||||||
Cost of revenue | 4,444 | 7,579 | 7,792 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (2,515) | (5,608) | (5,190) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | 477 | 328 | |||||||
Tax Rate | |||||||||
NOPAT | (2,515) | (6,084) | (5,518) | ||||||
Net income | (3,099) -47.79% | (5,935) 3.46% | (5,736) 108.72% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 2,195 | 3,115 | |||||||
BB yield | -2,898.86% | -26,749.49% | |||||||
| Debt | |||||||||
Debt current | 2,353 | 3,391 | 2,046 | ||||||
Long-term debt | 531 | 672 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | 3,606 | ||||||||
Net debt | (9,187) | (13,306) | (13,478) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (1,928) | (81) | 268 | ||||||
CAPEX | (7) | (71) | (62) | ||||||
Cash from investing activities | 26 | (12) | (47) | ||||||
Cash from financing activities | (2,624) | 2,942 | 1,595 | ||||||
FCF | (1,812) | (5,762) | (5,320) | ||||||
| Balance | |||||||||
Cash | 12,070 | 17,368 | 15,524 | ||||||
Long term investments | |||||||||
Excess cash | 11,974 | 17,270 | 15,394 | ||||||
Stockholders' equity | (21,385) | (20,897) | (14,570) | ||||||
Invested Capital | 37,963 | 39,345 | 31,873 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 867 | 267 | 42 | ||||||
Price | 1.68 492.38% | 0.28 1.29% | 0.28 -84.78% | ||||||
Market cap | 1,457 1,824.71% | 76 550.15% | 12 -78.01% | ||||||
EV | (7,730) | (13,230) | (13,466) | ||||||
EBITDA | (2,312) | (5,357) | (4,870) | ||||||
EV/EBITDA | 3.34 | 2.47 | 2.77 | ||||||
Interest | 544 | 477 | 218 | ||||||
Interest/NOPBT | |||||||||